Millipore has introduced the CellCiphr Cytotoxicity Profiling Assay Kit using human HepG2 cells
Millipore's Bioscience Division has developed the new assay panel to effectively detect drug-induced hepatotoxicity and the kit is expected to be used early in the drug discovery process.
The CellCiphr Cytotoxicity Profiling Panel uses human HepG2 cells in an assay comprised of high quality, validated, multiplexed detection reagents and protocols for testing pre-clinical compounds against well recognised cytotoxicity parameters.
The assay was developed in collaboration with Cellumen and its proprietary Cellular Systems Biology approach to investigating cytotoxicity.
Hence, profiling compounds with this assay panel takes advantage of the imaging, sensitivity and multiplexing capability of high content screening instruments (HCS).
The ability to recognise potential hepatotoxicity sooner in the drug development pipeline may reduce the cost of identifying toxicity in expensive animal studies.
The CellCiphr Panel provides multiplexed HCS analysis of 11 human cytotoxicity parameters over three time points (acute at 30 minutes, early at 24 hours and chronic at 72 hours), generating 10-point dose response curves in duplicate for up to 16 test compounds and four control toxins.
Millipore's Bioscience Division aims to develop innovative tools, services and biological reagents.
The Division's developments support in biomedical and academic researchers seeking to discover and develop new pharmaceuticals.
